Results 141 to 150 of about 5,784 (166)

Therapeutic Strategies Targeting the Tumor-Stromal Microenvironment in Colorectal Cancer: A Narrative Review. [PDF]

Target Oncol
Heilijgers F, Bakker MC, van Hest B, Franken I, Speetjens FM, Peeters KCMJ, Roodhart J, Mesker WE.   +7 more
europepmc   +1 more source

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]

Ann Med
Tan S, Li Y, Cao Y, Sun W, Hui W.
europepmc   +1 more source

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi-Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De-Differentiated Chondrosarcoma. [PDF]

Cancer Rep (Hoboken)
Youssef M, Grimison P.
europepmc   +1 more source

NSUN4-mediated m5C RNA methylation protects retinal cells against excitotoxic injury via the SHH signaling pathway. [PDF]

PLoS One
Li Y, Li D, Geng C, Wei R, Duan Y.
europepmc   +1 more source

Inherent tissue homeostasis of the juvenile metaphysis provides a foundation for osteosarcoma development. [PDF]

Nat Commun
Saito M, Nakasuka F, Sankoda N, Wang Y, Taguchi J, Ohta S, Yamada Y, Ozawa M, Sakurai S, Kondo A, Ushiku T, Nakayama R, Nakamura M, Takayanagi H, Shibata A, Yamamoto T, Yamada Y.   +16 more
europepmc   +1 more source

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

Journal of the American Academy of Dermatology, 2014
Background: Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administration (FDA) approved for advanced basal cell carcinomas (BCCs) based on a single, nonrandomized, phase-II trial. Consequently, additional clinical data are
John D Hainsworth, Anne Lynn S. Chang
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma

EClinicalMedicine, 2021
Laurent Mortier, Pierre Guerreschi, Philippe Saiag   +2 more
exaly  

The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo

Pharmaceutics, 2021
Maria Natalia Calienni, C Facundo Temprana, Fernando C Alvira   +2 more
exaly